Small interfering ribonucleic acid for cholesterol lowering – Inclisiran
Author:
Funder
Novartis Pharmaceuticals Corporation
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference31 articles.
1. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Arnett;J Am Coll Cardiol,2019
2. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association;McClellan;Circulation,2019
3. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel;Ference;Eur Heart J,2017
4. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9;German;Biodrugs,2020
5. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial;Giugliano;Lancet,2017
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Real-world experience of inclisiran prescription at the University of Pennsylvania Health Systems;Journal of Clinical Lipidology;2024-07
2. Evolving Concepts of the SCORE System: Subtracting Cholesterol from Risk Estimation: A Way for a Healthy Longevity?;Life;2024-05-24
3. Lipid-lowering therapy with inclisiran in the real-world setting: Initial data from a national health care service;Journal of Clinical Lipidology;2024-05
4. Monocytic microRNAs—Novel targets in atherosclerosis therapy;British Journal of Pharmacology;2024-04-04
5. Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran;Journal of the American Heart Association;2024-03-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3